JP2020500186A - メチオニンの生体共役のためのレドックスベースの試薬 - Google Patents

メチオニンの生体共役のためのレドックスベースの試薬 Download PDF

Info

Publication number
JP2020500186A
JP2020500186A JP2019524401A JP2019524401A JP2020500186A JP 2020500186 A JP2020500186 A JP 2020500186A JP 2019524401 A JP2019524401 A JP 2019524401A JP 2019524401 A JP2019524401 A JP 2019524401A JP 2020500186 A JP2020500186 A JP 2020500186A
Authority
JP
Japan
Prior art keywords
protein
methionine
polypeptide
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019524401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500186A5 (enExample
Inventor
リン，シーシャン
ヤン，シャオユウ
トーステ，エフ．・ディーン
チャン，クリストファー・ジェー．
Original Assignee
リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア
リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア, リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア filed Critical リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア
Publication of JP2020500186A publication Critical patent/JP2020500186A/ja
Publication of JP2020500186A5 publication Critical patent/JP2020500186A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G01N33/6815—Assays for specific amino acids containing sulfur, e.g. cysteine, cystine, methionine, homocysteine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/10—Analysis or design of chemical reactions, syntheses or processes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/70—Machine learning, data mining or chemometrics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/04—Oxidoreductases acting on sulfur groups as donors (1.8) with a disulfide as acceptor (1.8.4)
    • C12Y108/04013—L-Methionine (S)-S-oxide reductase (1.8.4.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/04—Oxidoreductases acting on sulfur groups as donors (1.8) with a disulfide as acceptor (1.8.4)
    • C12Y108/04014—L-Methionine (R)-S-oxide reductase (1.8.4.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Theoretical Computer Science (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Software Systems (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Toxicology (AREA)
JP2019524401A 2016-11-14 2017-11-13 メチオニンの生体共役のためのレドックスベースの試薬 Pending JP2020500186A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662421825P 2016-11-14 2016-11-14
US62/421,825 2016-11-14
US201762583517P 2017-11-09 2017-11-09
US62/583,517 2017-11-09
PCT/US2017/061412 WO2018089951A1 (en) 2016-11-14 2017-11-13 Redox-based reagents for methionine bioconjugation

Publications (2)

Publication Number Publication Date
JP2020500186A true JP2020500186A (ja) 2020-01-09
JP2020500186A5 JP2020500186A5 (enExample) 2020-11-26

Family

ID=62109289

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019524401A Pending JP2020500186A (ja) 2016-11-14 2017-11-13 メチオニンの生体共役のためのレドックスベースの試薬

Country Status (5)

Country Link
US (1) US11353463B2 (enExample)
EP (1) EP3538087A4 (enExample)
JP (1) JP2020500186A (enExample)
CN (1) CN110177550A (enExample)
WO (1) WO2018089951A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020036904A1 (en) * 2018-08-13 2020-02-20 The Regents Of The University Of California Novel urea-oxaziridines
US12642864B2 (en) * 2018-12-28 2026-06-02 The Regents Of The University Of California Methionine containing antibodies for conjugation of agents
CN109627300B (zh) * 2019-02-18 2022-08-05 浙江新银象生物工程有限公司 Nisin溶液稳定剂开发及应用
CN113092309B (zh) * 2021-04-13 2022-01-28 福州大学 一种毛细管高度指示剂装置及其检测硫化氢的应用
EP4499617A1 (en) * 2022-03-29 2025-02-05 Novartis AG An oxaziridine platform for targeting functional allosteric methionine sites

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200626532A (en) * 2004-09-21 2006-08-01 Syngenta Participations Ag Novel insecticides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TETRAHEDRON LETTERS, vol. 44, JPN6021036652, 2003, pages 5335 - 5338, ISSN: 0004753429 *

Also Published As

Publication number Publication date
CN110177550A (zh) 2019-08-27
WO2018089951A1 (en) 2018-05-17
US11353463B2 (en) 2022-06-07
US20190257838A1 (en) 2019-08-22
EP3538087A4 (en) 2020-02-12
EP3538087A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
US11353463B2 (en) Redox-based reagents for methionine bioconjugation
Reddy et al. Chemical methods for modification of proteins
Tamura et al. Chemistry for covalent modification of endogenous/native proteins: from test tubes to complex biological systems
Lin et al. Redox-based reagents for chemoselective methionine bioconjugation
JP7232533B2 (ja) Ｒａｓ抑制性ペプチドおよびその使用
Murale et al. Photo-affinity labeling (PAL) in chemical proteomics: a handy tool to investigate protein-protein interactions (PPIs)
Peng et al. Functional analysis of protein post‐translational modifications using genetic codon expansion
Alcock et al. Norbornene probes for the study of cysteine oxidation
US20240216524A1 (en) Chemoselective Rapid Azo-Coupling Reaction for Bioconjugation
Khan et al. Influence of the diversified structural variations at the imine functionality of 4-bromophenylacetic acid derived hydrazones on alkaline phosphatase inhibition: synthesis and molecular modelling studies
US12493045B2 (en) Multi-target crosslinkers and uses thereof
WO2018234483A1 (en) Tunable probes for selective protein labelling and enzyme inhibition
US11155530B2 (en) Urea-oxaziridines
Jänsch et al. 3‐Chloro‐5‐Substituted‐1, 2, 4‐Thiadiazoles (TDZs) as Selective and Efficient Protein Thiol Modifiers
Söveges et al. Tracking down protein–protein interactions via a FRET-system using site-specific thiol-labeling
JP2023534313A (ja) フォトレドックスタンパク質修飾
Wei et al. Alkenylation of cys-containing peptides with thianthrenium salts via thio-addition-migration
Svenningsen et al. The covalent reactivity of functionalized 5-hydroxy-butyrolactams is the basis for targeting of fatty acid binding protein 5 (FABP5) by the neurotrophic agent MT-21
JP7007292B2 (ja) 薬剤としての使用のため、特にパーキンソン病の治療のための新規二環式化合物
Kadambar et al. Selective Derivatization of Hexahistidine-Tagged Recombinant Proteins
Tessier et al. Chapter IV. Ethynylation of Cysteine Residues: From Peptides to Proteins in Vitro and in Living Cells
WO2025250949A1 (en) Compositions and methods for chemoproteomic interaction site mapping
Wang The Chemical Synthetic Investigation of Proteins with Site-specific Lysine Post-Translational Modifications
Hughes Selective N-terminal Protein Bioconjugation Enabled by Conjugate Addition/Ring Expansion (CARE) Cascades
CN120882733A (zh) 用于共价靶向的修饰蛋白质或肽

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220419